LETTERS to the EDITORCyclophosphamide and plasma exchange in multiple sclerosis
References (10)
- et al.
Chronic progressive multiple sclerosis: double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs
Neurology
(1985) - et al.
Intensive immunosuppression in progressive multiple sclerosis: a randomised, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH
N Engl J Med
(1983) - et al.
IV cyclophosphamide ACTH plus maintenance cyclophosphamide boosters in progressive MS: final report of the Northeast Cooperative Treatment Group
Neurology
(1991) - et al.
Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial
Neurology
(1990) - et al.
Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis
Arch Neurol
(1989)
Cited by (39)
Multiple Sclerosis
2016, International Encyclopedia of Public HealthDefinitions of Breakthrough Disease and Second-Line Agents
2011, Neurologic ClinicsCitation Excerpt :In modern practice, cyclophosphamide is typically used either as a high-dose induction therapy for fulminant MS or as booster administered every 1 to 3 months.18,19 There has been great debate in the literature about the merits of cyclophosphamide administration in MS, with the main North American trials producing divergent results, likely related to the clinical characteristics of the enrolled patients.18–23 An early unblinded randomized controlled trial (RCT) of 60 patients with chronic progressive MS (CPMS) compared cyclophosphamide induction and adrenocorticotropic hormone (ACTH); oral cyclophosphamide, plasma exchange, and ACTH; and ACTH alone.24
Immunosuppressive therapy for multiple sclerosis
2005, Neurologic ClinicsCitation Excerpt :This study was randomized, placebo controlled, and single masked and included a third treatment group that received plasma exchange with oral cyclophosphamide and prednisone. The failure of the Kaiser and Canadian studies to find a benefit of cyclophosphamide therapy led to controversy in the literature over its use; this debate occurred before our current understanding of anti-inflammatory therapy in MS and the use of MRI to measure inflammatory lesions with contrast-enhanced images [9,19,28–30]. A strict comparison of the trials is impractical because of differing trial designs, patient selection, and treatment regimens.
Multiple Sclerosis: Therapy
2004, Myelin Biology and DisordersTherapeutic Plasma Exchange
2003, Office Practice of NeurologyMultiple Sclerosis
2003, Neurological Disorders: Course and Treatment: Second Edition